Milestone Pharmaceuticals INC Schedule 13G passive stakes

Pavaki Capital Management LLC, Pavaki Capital Partners LP, and Ashok Rambhai Patel have collectively acquired a 7.3% stake in Milestone Pharmaceuticals Inc., holding 9,067,848 shares.

RTW Investments, LP and Roderick Wong disclose beneficial ownership of 9.9% of Milestone Pharmaceuticals Inc. common shares, holding 12,356,953 shares.

Adage Capital Management, L.P. has reported beneficial ownership of 8,000,000 common shares of Milestone Pharmaceuticals Inc., representing 6.37% of the class, primarily through warrants.

Trails Edge Capital Partners, LP and affiliates have filed an amended Schedule 13G, disclosing their beneficial ownership in Milestone Pharmaceuticals Inc. has fallen to 4.3%.

Propel Bio Management, Leen Kawas, Richard Kayne, and Propel Bio Partners have disclosed a 9.99% beneficial ownership stake in Milestone Pharmaceuticals Inc., including shares from a recent offering and warrant exercises.

Trails Edge Capital Partners, LP, along with its affiliates, has disclosed a 9.9% beneficial ownership stake in Milestone Pharmaceuticals Inc., primarily through common shares and exercisable warrants.

RTW Investments, LP and Roderick Wong, M.D. report a 9.99% beneficial ownership stake in Milestone Pharmaceuticals Inc. through a Schedule 13G/A filing.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 9.99% beneficial ownership stake in Milestone Pharmaceuticals Inc. as of September 30, 2025.

Trails Edge Capital Partners, LP, along with its affiliates, has reported a 9.9% beneficial ownership stake in Milestone Pharmaceuticals Inc., totaling 8,847,882 common shares.

Millennium Management LLC and its affiliates, including Integrated Core Strategies (US) LLC and Millennium Group Management LLC, along with Israel A. Englander, have disclosed a passive beneficial ownership of 0.6% in Milestone Pharmaceuticals Inc., totaling 322,082 common shares.

BlackRock, Inc. has filed an amended Schedule 13G indicating it no longer holds any beneficial ownership in Milestone Pharmaceuticals Inc., reducing its stake to 0.0%.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a continued beneficial ownership of 9.99% in Milestone Pharmaceuticals Inc., as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 7.6% beneficial ownership stake in Milestone Pharmaceuticals Inc. as of December 31, 2024.